作者
Hua-Hao Fan, Li-Qin Wang, Wen-Li Liu, Xiao-Ping An, Zhen-Dong Liu, Xiao-Qi He, Li-Hua Song, Yi-Gang Tong
发表日期
2020/5/1
期刊
Chinese medical journal
卷号
133
期号
09
页码范围
1051-1056
出版商
Chinese Medical Journals Publishing House Co., Ltd.
简介
Background
Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV-related coronavirus model.
Methods
A 2019-nCoV-related pangolin coronavirus GX_P2V/pangolin/2017/Guangxi was described. Whether GX_P2V uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA)-mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic …
学术搜索中的文章
HH Fan, LQ Wang, WL Liu, XP An, ZD Liu, XQ He… - Chinese medical journal, 2020
F Hua-Hao, W Li-Qin, L Wen-Li, A Xiao-Ping… - Chinese Medical Journal, 2020